Michael Jennings, MD
Urology · Gadsden, ALNPI 1508271578
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,300 of the $8,783 with a category attached, or 71.7%. It is spread thinly across 35 manufacturers, the largest accounting for just 15.7%. Reporting peaked in 2023 at $2,514 and has fallen 73.9% since, to $655 in 2025.
Across 221 payments — averaging $39.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$1K
- Axonics, Inc.$1K
- Intuitive Surgical$1K
- Coloplast$959
- Boston Scientific$829
- Astellas Pharma US Inc$456
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$2583%
- Travel & lodging$1,96822%
- Food & beverage$6,30072%
- Education$2583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 9 | $1,378 |
| Axonics, Inc. | 31 | $1,351 |
| Intuitive Surgical | 4 | $1,287 |
| Coloplast | 14 | $959 |
| Boston Scientific | 13 | $829 |
| Astellas Pharma US Inc | 22 | $456 |
| Johnson & Johnson(3 entities) | 13 | $315 |
| KARL Storz Endoscopy-america | 2 | $268 |
| AbbVie(2 entities) | 14 | $205 |
| Endo Pharmaceuticals Inc. | 13 | $205 |
| Medtronic(2 entities) | 5 | $181 |
| Endo USA, Inc. | 8 | $175 |
| Pfizer | 7 | $144 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $136 |
| Sumitomo Pharma America, Inc. | 13 | $134 |
| Urovant Sciences Inc | 14 | $134 |
| Bayer | 5 | $88 |
| Olympus America Inc. | 4 | $68 |
| Procept Biorobotics Corporation | 2 | $67 |
| Urogen Pharma, Inc. | 3 | $64 |
| Myriad Genetic Laboratories, Inc. | 3 | $57 |
| Myovant Sciences Inc. | 2 | $35 |
| 180 Medical, Inc. | 1 | $26 |
| Kerecis Limited | 1 | $26 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Antares Pharma, Inc. | 1 | $24 |
| Travere Therapeutics, Inc. | 7 | $23 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Blue Earth Diagnostics | 1 | $18 |
| Bluewind Medical | 1 | $14 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
| Progenics Pharmaceuticals, Inc. | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,268
- UroLift System$1,207
- Axonics$732
- ALTIS$443
- TITAN$228
- 24FR BIPLR COAG ELECTRDE, STERILE, PKG/6$141
- Surgical wound closure product$136
- SOLYX BLUE$129
- CMOS VIDEO URETEROSCOPE, 8.5 FR. X 675MM$127
- Solyx SIS System$125
- AMS 700 CXR RTE KIT$115
- SOLYX$113
- GENERAL ERECTILE DYSFUNCTION$100
How this compares
$8,783 in reported general payments places this provider in the 80th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 42 | $552,982 |
| GemtesaVibegron | 242 | $145,284 |
| MyrbetriqMirabegron | 166 | $100,286 |
| OrgovyxRelugolix | 11 | $29,747 |
| Tamsulosin Hcl | 736 | $13,699 |
| ElmironPentosan Polysulfate Sodium | 14 | $12,883 |
| Silodosin | 75 | $5,572 |
| NitrofurantoinNitrofurantoin Macrocrystal | 144 | $4,383 |
| Estradiol | 37 | $3,332 |
| Cephalexin | 411 | $2,721 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 126 | $2,380 |
| Oxybutynin Chloride ErOxybutynin Chloride | 124 | $2,301 |
| Finasteride | 145 | $1,966 |
| Doxycycline Hyclate | 257 | $1,678 |
| Desmopressin Acetate | 18 | $1,081 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $88 | $552,98242 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $134 | $175,031253 claims |
| Astellas Pharma US IncMyrbetriq | $456 | $100,286166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 179 urology providers in Alabama.
Other urology in Gadsden
- John PiraniGadsden$6K
- Thomas ChiBirmingham$463K
- Joel FunkBirmingham$347K
- Adam BaumgartenBirmingham$271K
- Brian ChristineHomewood$215K
- Vincent BivinsHomewood$117K
- Kyle WoodBirmingham$91K
- Christopher KeelFairhope$68K
- Rachel EngelbergHomewood$61K
- Jeffrey NixBirmingham$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.